Alpine Immune Sciences. has filed a patent for variant CD80 polypeptides with therapeutic potential for immunological and oncological conditions. The claim focuses on a CD80-Fc fusion immunomodulatory protein containing specific amino acid substitutions. This innovation could lead to new treatments for various diseases. GlobalData’s report on Alpine Immune Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Alpine Immune Sciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Alpine Immune Sciences, Personalized cancer vaccines was a key innovation area identified from patents. Alpine Immune Sciences's grant share as of January 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.

Variant cd80-fc fusion protein for immunotherapy

Source: United States Patent and Trademark Office (USPTO). Credit: Alpine Immune Sciences Inc

A recently filed patent (Publication Number: US20240002466A1) discloses a CD80-Fc fusion immunomodulatory protein that includes a variant CD80 polypeptide and an Fc domain. The variant CD80 polypeptide contains specific amino acid substitutions, such as A71G or A71D, in the amino acid sequence of the IgV domain. This fusion protein exhibits increased binding affinity to the ectodomain of human PD-L1 compared to unmodified CD80, potentially enhancing its immunomodulatory properties.

Furthermore, the patent describes the production of the CD80-Fc fusion protein using nucleic acid molecules encoding the protein and vectors for expression in host cells. The protein can be used in various forms, including homodimers, conjugates linked to targeting moieties for specific cell binding, and pharmaceutical compositions for modulating immune responses in subjects. The Fc region of the fusion protein can be a variant with reduced effector function, and the protein may exhibit PD-L1-dependent CD28 costimulation. Overall, the patent covers a range of applications and methods related to this novel CD80-Fc fusion immunomodulatory protein, highlighting its potential in the field of immunotherapy.

To know more about GlobalData’s detailed insights on Alpine Immune Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies